Summary of t(11; 16)(q23; p13) in Patients With Treatment-Related Acute Leukemia
| Patient No. . | Age*/Sex . | Primary Malignancy . | Topo II Inhibitors . | Time to Leukemia . | Type of Leukemia . | Karyotype . | Length of Survival/Present Status . | PAC Results . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 10/F | AML-M2; t(8; 21) | Etoposide and Doxorubicin (600 mg/m2) + aa | 13 mo | t-MDS/t-AML (M4) to t-T-ALL | 46,XX,t(11; 16)(q23;p13)[18]46,idem,+12[14] | 26 mo†, post-BMT | Der(11) | Patient no. 19 |
| 2 | 64/F | Breast cancer | Doxorubicin + aa, G-CSF | 10 mo | t-AML (M4) | 46,XX,t(11; 16)(q23; p13.3)[23]/45,idem,−18[2] | Alive in remission as of 2/97 | Der(16) | 1 |
| 3 | 3/F | PreB-ALL; hyperdiploid | Etoposide (8,100 mg/m2) | 33 mo | t-AML (M2) | 46,XX,t(1; 12)(p36.1; q13),t(11; 16)(q23; p13.3)[13]/46,idem, del(7)(q31)[7] | 10 mo+; post-BMT | Split | Patient no. 76 |
| 4 | 11/M | Pre B-ALL | Etoposide (5,555 mg/m2) | 37 mo | t-AML (M4) | 46,XY,del(1)(p34.3p36.1), t(11; 16)(q23; p13.3)[12]/46,idem, t(2; 3)(p21; q21)[8] | 25 mo; post BMT† | Der(16) | |
| 5 | 74/M | Mantle cell lymphoma | Etoposide (2,200 mg) + aa | 19 mo | t-AML (M5a) | 47,XY,+8, t(11; 16)(q23; p13)[11]/48,idem,+8[3] | CR but early relapse <1 mo† | Der(16) | Patient no. 213 |
| 6 | 16/F | PNET | Etoposide (2,950 mg/m2) doxorubicin (375 mg/m2) + aa | 19 mo | t-MDS (CMML) | 46,XX,t(11; 16)(q23; p13)[17]/46,idem,i(17)(q10)[2]/46,XX[1] | BMT | Split | |
| 7 | 19/M | Ewing's sarcoma | Etoposide (5,000 mg/m2) doxorubicin (600 mg/m2) aa, x-ray, G-CSF | >6 mo | t-MDS | 46,XY,t(11; 16)(q23; p13)[13]/46,XY[7]‡ | Normal, healthy | Split | Patient no. 214 |
| 8 | 5/F | Neuroblastoma | Epipodophyllotoxin, aa | 28 mo | t-MDS | 46,XX,t(11; 16)(q23; p13)[19]/46,XX[1] | 13 mo | Split | |
| 9 | 14/F | T-ALL; 46,XX,t(11; 14) (p13; q11) | Teniposide | 5 yr | t-MDS t-AML (M4) | 46,XX,del(6)(p23),t(11; 16)(q23; p13)[4]/46,XX[6] | 2 yr+ | Patient no. 618 | |
| 10 | M | T-ALL; 46,XY | Teniposide and doxorubicin | 21 mo | t-B-ALL | 46,XY,t(5; 8)(q33; q12),t(11; 16)(q23; p13)[21]/46,XY[3] | Patient 312 | ||
| 11 | 7/M | B-ALL; 46,XY | Pirarubicin (300 mg/m2) | 29 mo | t-MDS (CMML) | 46,XY,t(11; 16)(q23; p13)[?] | 19 |
| Patient No. . | Age*/Sex . | Primary Malignancy . | Topo II Inhibitors . | Time to Leukemia . | Type of Leukemia . | Karyotype . | Length of Survival/Present Status . | PAC Results . | Reference . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 10/F | AML-M2; t(8; 21) | Etoposide and Doxorubicin (600 mg/m2) + aa | 13 mo | t-MDS/t-AML (M4) to t-T-ALL | 46,XX,t(11; 16)(q23;p13)[18]46,idem,+12[14] | 26 mo†, post-BMT | Der(11) | Patient no. 19 |
| 2 | 64/F | Breast cancer | Doxorubicin + aa, G-CSF | 10 mo | t-AML (M4) | 46,XX,t(11; 16)(q23; p13.3)[23]/45,idem,−18[2] | Alive in remission as of 2/97 | Der(16) | 1 |
| 3 | 3/F | PreB-ALL; hyperdiploid | Etoposide (8,100 mg/m2) | 33 mo | t-AML (M2) | 46,XX,t(1; 12)(p36.1; q13),t(11; 16)(q23; p13.3)[13]/46,idem, del(7)(q31)[7] | 10 mo+; post-BMT | Split | Patient no. 76 |
| 4 | 11/M | Pre B-ALL | Etoposide (5,555 mg/m2) | 37 mo | t-AML (M4) | 46,XY,del(1)(p34.3p36.1), t(11; 16)(q23; p13.3)[12]/46,idem, t(2; 3)(p21; q21)[8] | 25 mo; post BMT† | Der(16) | |
| 5 | 74/M | Mantle cell lymphoma | Etoposide (2,200 mg) + aa | 19 mo | t-AML (M5a) | 47,XY,+8, t(11; 16)(q23; p13)[11]/48,idem,+8[3] | CR but early relapse <1 mo† | Der(16) | Patient no. 213 |
| 6 | 16/F | PNET | Etoposide (2,950 mg/m2) doxorubicin (375 mg/m2) + aa | 19 mo | t-MDS (CMML) | 46,XX,t(11; 16)(q23; p13)[17]/46,idem,i(17)(q10)[2]/46,XX[1] | BMT | Split | |
| 7 | 19/M | Ewing's sarcoma | Etoposide (5,000 mg/m2) doxorubicin (600 mg/m2) aa, x-ray, G-CSF | >6 mo | t-MDS | 46,XY,t(11; 16)(q23; p13)[13]/46,XY[7]‡ | Normal, healthy | Split | Patient no. 214 |
| 8 | 5/F | Neuroblastoma | Epipodophyllotoxin, aa | 28 mo | t-MDS | 46,XX,t(11; 16)(q23; p13)[19]/46,XX[1] | 13 mo | Split | |
| 9 | 14/F | T-ALL; 46,XX,t(11; 14) (p13; q11) | Teniposide | 5 yr | t-MDS t-AML (M4) | 46,XX,del(6)(p23),t(11; 16)(q23; p13)[4]/46,XX[6] | 2 yr+ | Patient no. 618 | |
| 10 | M | T-ALL; 46,XY | Teniposide and doxorubicin | 21 mo | t-B-ALL | 46,XY,t(5; 8)(q33; q12),t(11; 16)(q23; p13)[21]/46,XY[3] | Patient 312 | ||
| 11 | 7/M | B-ALL; 46,XY | Pirarubicin (300 mg/m2) | 29 mo | t-MDS (CMML) | 46,XY,t(11; 16)(q23; p13)[?] | 19 |
Abbreviations: AML-M2, acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; BMT, bone marrow transplant; CMML, chronic myelomonocytic leukemia; CR, complete remission; MDS, myelodysplastic syndrome; PNET, peripheral neuroepithelioma; aa, alkylating agents.
Age at diagnosis of first malignancy.
Dead.
Without treatment, percentage of abnormal metaphase cells decreased and disappeared 12 months after original pancytopenia; his peripheral counts also became normal.